Loading…
Journey Medical Corporation is projected to rise to $7.26 by 2027, a +14% move from its current price of $6.37. DERM is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $6.18 | $6.37 | $6.57 | +0.02% |
| Aug 5 | $6.10 | $6.37 | $6.65 | +0.05% |
| Aug 6 | $6.05 | $6.37 | $6.72 | +0.07% |
| Aug 7 | $6.00 | $6.38 | $6.78 | +0.09% |
| Aug 8 | $5.96 | $6.38 | $6.83 | +0.11% |
| Aug 9 | $5.92 | $6.38 | $6.87 | +0.14% |
| Aug 10 | $5.89 | $6.38 | $6.92 | +0.16% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.89 | $6.38 | $6.92 | +0.16% |
| Week 2 | $5.70 | $6.39 | $7.16 | +0.32% |
| Week 3 | $5.57 | $6.40 | $7.36 | +0.48% |
| Week 4 | $5.46 | $6.41 | $7.53 | +0.64% |
| Week 5 | $5.36 | $6.42 | $7.69 | +0.80% |
| Week 6 | $5.28 | $6.43 | $7.83 | +0.96% |
| Week 7 | $5.21 | $6.44 | $7.97 | +1.12% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Journey Medical Corporation is a healthcare company focused on the development and commercialization of pharmaceutical products for dermatological conditions in the United States. Its marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first- and second-degree burns, including sunburns and radiation dermatitis.
Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
The company was formerly known as Coronado Dermatology, Inc. and operates in the healthcare sector with a focus on dermatology products and treatments across the United States.
Journey Medical Corporation (DERM) is a healthcare company in the dermatology space with a current price of $6.19 and a market cap of $170.44M. It holds a rank of 3697. The near-term trajectory shows a flat to modestly rising path, with the 2026 forecast averaging $6.19 and yielding 0% ROI, and the path gradually turning more bullish in subsequent years.
Forecasts project a rising average price over time, reaching $10.38 in 2030 (ROI 67.7) and then scaling to $26.85 by 2040 (ROI 333.8) and $64.21 by 2050 (ROI 937.3). These figures imply a multi-year expansion, with bullish momentum evident in later years, albeit with inherent uncertainty and variability in annual outcomes.
A major floor 31.1% below — a decisive break under it would weaken the trend.
The nearest floor, 3.5% below — buyers have tended to step in here.
The nearest ceiling, 14.8% above — a clean break opens room to run.
A major ceiling 22.0% above — clearing it would confirm fresh momentum.
Key DERM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of DERM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.33 | Buy | $6.39 | Sell |
| MA 10 | $6.59 | Sell | $6.53 | Sell |
| MA 20 | $6.80 | Sell | $6.63 | Sell |
| MA 50 | $6.51 | Sell | $6.52 | Sell |
| MA 100 | $6.10 | Buy | $6.53 | Sell |
| MA 200 | $7.07 | Sell | $6.69 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 45.02 | Neutral |
| Stoch RSI (14) | 22.98 | Neutral |
| CCI (20) | -85.42 | Neutral |
| Williams %R (14) | -81.03 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -12.38 | Sell |
| Bollinger %B (20,2) | 0.21 | Neutral |
| Stochastic %K (14) | 18.97 | Buy |
| TRIX (15) | 0.13 | Buy |
| Awesome (5,34) | -0.37 | Sell |
| Ultimate (7,14,28) | 34.91 | Neutral |
| Momentum (10) | -0.79 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 6.21 | Buy |
| ADX (14) | 15.96 | Neutral |
| ATR (14) | 0.20 | Info |
The 30-day technical picture is neutral. The RSI(14) is at 50, and the short-term trend sits between neutral and stability. The price trades around the SMA50 of $6.46 and remains below the SMA200 of $7.10, indicating a mixed near-term rhythm.
Support sits at $5.92 and resistance at $7.31, framing a concise near-term range. The 30-day price corridor spans from $5.05 to $7.59, suggesting limited downside and a potential upside cap near the resistance level unless momentum shifts.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $4.39 | $6.37 | $8.80 | 0% | Neutral | |
| $5.73 | $7.26 | $9.76 | +14% | Neutral | |
| $5.94 | $7.77 | $10.89 | +22% | Bullish | |
| $6.75 | $9.07 | $13.12 | +42% | Bullish | |
| $7.74 | $10.65 | $15.82 | +67% | Bullish | |
| $9.86 | $13.84 | $21.06 | +117% | Bullish | |
| $10.55 | $15.11 | $23.47 | +137% | Bullish | |
| $9.92 | $14.48 | $22.91 | +127% | Bullish | |
| $10.99 | $16.33 | $26.29 | +156% | Bullish | |
| $11.70 | $17.68 | $28.93 | +178% | Bullish | |
| $16.78 | $27.41 | $47.95 | +330% | Bullish | |
| $35.38 | $66.19 | $127.53 | +939% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $4.39 | $6.37 | $7.94 | +0.00% |
| September 2026 | $5.56 | $6.59 | $8.06 | +3.52% |
| October 2026 | $5.44 | $6.50 | $8.05 | -1.37% |
| November 2026 | $5.59 | $6.73 | $8.41 | +3.46% |
| December 2026 | $5.77 | $6.99 | $8.80 | +3.84% |
Click any year to see its month-by-month DERM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, DERM is projected to trade between $4.39 and $8.80, averaging $6.37 — a potential gain of 0% from today's $6.37. A consolidation phase looks the most probable path here.
Journey Medical Corporation's 2027 outlook centres on $7.26, within a $5.73 to $9.76 range. That is up +14% on the projected 2026 average. That marks a +14% change versus current levels. Price action looks broadly range-bound.
By 2028, DERM could reach as high as $10.89, with a base case around $7.77 and support toward $5.94 — roughly +22% from $6.37. Buyers look set to stay in control over this stretch.
Expect DERM to range from $6.75 to $13.12 through 2029. The $9.07 average target implies a +42% move from current prices. That is up +17% on the projected 2028 average. Momentum favours further upside here.
The DERM price prediction for 2030 points to an average of $10.65 (low $7.74, high $15.82) — a potential gain of +67% on today's $6.37. Buyers look set to stay in control over this stretch.
In 2031, DERM is projected to trade between $9.86 and $21.06, averaging $13.84 — a potential gain of +117% from today's $6.37. That is up +30% on the projected 2030 average. Momentum favours further upside here.
Journey Medical Corporation's 2032 outlook centres on $15.11, within a $10.55 to $23.47 range. That is up +9% on the projected 2031 average. That marks a +137% change versus current levels. Buyers look set to stay in control over this stretch.
By 2033, DERM could reach as high as $22.91, with a base case around $14.48 and support toward $9.92 — roughly +127% from $6.37. Momentum favours further upside here.
Expect DERM to range from $10.99 to $26.29 through 2034. The $16.33 average target implies a +156% move from current prices. That is up +13% on the projected 2033 average. Buyers look set to stay in control over this stretch.
The DERM price prediction for 2035 points to an average of $17.68 (low $11.70, high $28.93) — a potential gain of +178% on today's $6.37. Momentum favours further upside here.
In 2040, DERM is projected to trade between $16.78 and $47.95, averaging $27.41 — a potential gain of +330% from today's $6.37. That is up +55% on the projected 2035 average. Buyers look set to stay in control over this stretch.
Journey Medical Corporation's 2050 outlook centres on $66.19, within a $35.38 to $127.53 range. That is up +141% on the projected 2040 average. That marks a +939% change versus current levels. Momentum favours further upside here.
Investing $1,000 in DERM today (≈ 156.985871 DERM) could be worth
$10,390.93
+$9,390.93 (+939%) by 2050 · US Dollar
Based on the average projected DERM price of $66.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in DERMwould be worth at today's price.
$1,000 invested in DERM on Jul 31, 2025 (≈ 136.054424 DERM) would be worth
$866.67
-$133.33 (-13.3%) today · 0.87× · US Dollar
Based on a DERM entry price of $7.35 vs. today's $6.37.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.19 | $1,029.08 | +2.9% |
| 1 month ago | $7.04 | $904.83 | -9.5% |
| 3 months ago | $5.19 | $1,227.36 | +22.7% |
| 6 months ago | $8.59 | $741.56 | -25.8% |
| 1 year ago | $7.35 | $866.67 | -13.3% |
| All time (4.7y) ago | $9.9 | $643.43 | -35.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our DERM forecast.
Our base-case forecast reaches $13.00 around 2031.
Implied market cap at $13.00: $279.95M
Looking further ahead, the multi-year forecast points to a bullish trajectory. In 2030, the average price is forecast at $10.38 with a minimum of $7.52 and a maximum of $15.49, yielding a 67.7% ROI and a bullish sentiment. By 2040, the average rises to $26.85 with a maximum of $47.28 and a 333.8% ROI, reinforcing a strong bullish outlook.
By 2050, the average is forecast at $64.21 with a maximum of $124.65 and a striking 937.3% ROI, continuing the bullish narrative. The long-range path suggests substantial upside potential, but the figures are estimates and subject to market dynamics, regulatory factors, and company performance. These projections are not guarantees and should be weighed with inherent investment uncertainties.
Tap a question to reveal the answer.
In 2030, the forecasted average price is $10.38, with a minimum of $7.52 and a maximum of $15.49, and an ROI of 67.7%; sentiment is BULLISH.
Forecasts show a bullish trajectory over time, with the average price rising from $6.19 in 2026 to higher levels such as $10.38 in 2030, and up to $64.21 by 2050, accompanied by rising ROI (e.g., 67.7% in 2030 and 937.3% in 2050). However, these are estimates and not guarantees.
The 2050 maximum forecast is $124.65, which would exceed $100, with an ROI of 937.3% and a bullish outlook.
Current price is $6.19 and market cap is $170.44M.
Near-term sentiment is NEUTRAL with RSI(14) at 50. The stock trades around the SMA50 of $6.46 and below the SMA200 of $7.10, with a 30-day range from $5.05 to $7.59.
Journey Medical Corporation Community Discussion
0Share your Journey Medical Corporation price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.